Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MRPS5 (ImmuneEditome ID:64969)

1. Gene summary of enriched editing regions for MRPS5

Gene summary

Gene information	Gene symbol	MRPS5
	Gene ID	64969
	GeneSynonyms	MRP-S5\|S5mt
	GeneCytomap	2q11.1
	GeneType	protein-coding
	GeneDescription	28S ribosomal protein S5, mitochondrial\|mitochondrial 28S ribosomal protein S5\|mitochondrial small ribosomal subunit protein uS5m
	GeneModificationdate	20230329
	UniprotID	P82675
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr2:95135484-95136037:-	ENST00000475040.1	ENSG00000144029.10	MRPS5	ncRNA_intronic	L1M4,AluJo,AluSc	chr2:95135484-95136037:-.alignment
chr2:95145291-95146745:-	ENST00000475040.1	ENSG00000144029.10	MRPS5	ncRNA_intronic	MER4D1,MER4E1,MER4D	chr2:95145291-95146745:-.alignment

Top

2. Tumor-specific enriched editing regions for MRPS5

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr2:95145291-95146745:-	BRCA	EER	1.3763e-03
ENSG00000144029.10,MRPS5	BRCA	EAG	6.0962e-04
chr2:95145291-95146745:-	THCA	EER	6.5491e-03
ENSG00000144029.10,MRPS5	THCA	EAG	9.7049e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr2:95145291-95146745:-	KIRP	Cli	EER	2.6065e-02	8.1451e-03	0.2079
ENSG00000144029.10,MRPS5	KIRP	Cli	EAG	2.8189e-02	8.9008e-03	0.2056

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for MRPS5

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr2:95145291-95146745:-

GBM

EER

ENSG00000136315,RP11-84C10.2

0.2633

2.9962e-02

3.7468e-07

0.4084

T_cells_CD4_memory_activated

GSVA_HALLMARK_INFLAMMATORY_RESPONSE

chr2:95145291-95146745:-

UCEC

EER

ENSG00000104814,MAP4K1

0.3197

1.6663e-02

2.4184e-07

0.4198

MAP4K1

T_cells_CD8

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr2:95145291-95146745:-

UCEC

EER

ENSG00000157303,SUSD3

0.3101

1.9550e-02

3.5321e-10

0.4989

Macrophages_M1

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

chr2:95145291-95146745:-

UCEC

EER

ENSG00000204839,MROH6

0.2826

3.8284e-02

3.6534e-07

0.4141

Macrophages_M0

GSVA_HALLMARK_KRAS_SIGNALING_DN

chr2:95145291-95146745:-

UCEC

EER

ENSG00000144029,MRPS5

0.2809

4.2562e-02

8.7310e-08

0.4336

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr2:95145291-95146745:-

UCEC

EER

ENSG00000105639,JAK3

0.2775

4.6910e-02

4.3367e-07

0.4117

JAK3

T_cells_CD4_memory_activated

GSVA_HALLMARK_PEROXISOME

chr2:95145291-95146745:-

KIRP

EER

ENSG00000261879,RP11-333E1.1

-0.3629

1.3914e-06

4.3402e-11

-0.4105

Mast_cells_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr2:95145291-95146745:-

KIRP

EER

ENSG00000198920,KIAA0753

-0.3464

3.3487e-06

2.2581e-11

-0.4159

Mast_cells_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr2:95145291-95146745:-

ESCA

EER

ENSG00000168763,CNNM3

-0.4492

6.4688e-05

2.8404e-07

-0.4083

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HYPOXIA

chr2:95145291-95146745:-

ESCA

EER

ENSG00000186230,ZNF749

-0.4504

7.2031e-05

4.0864e-07

-0.4033

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

More results

Top

4. Enriched editing regions and immune related splicing for MRPS5

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr2:95145291-95146745:-

BLCA

EER

ENSG00000196754.6

chr1

153561511:153561588:153563733:153563853:153565505:153565542

-0.1246

3.3998e-02

3.1425e-12

-0.4199

Plasma_cells

chr2:95145291-95146745:-

BLCA

EER

ENSG00000196754.6

chr1

153561511:153561588:153563733:153563887:153565505:153565542

-0.1246

3.3998e-02

3.1425e-12

-0.4199

Plasma_cells

chr2:95145291-95146745:-

BLCA

EER

ENSG00000196754.6

chr1

153561511:153561588:153563733:153563881:153565505:153565542

-0.1216

3.9205e-02

9.2468e-13

-0.4347

Plasma_cells

chr2:95145291-95146745:-

ESCA

EER

ENSG00000163625.11

chr4

84803289:84803467:84808333:84808417:84809886:84810107

-0.3226

1.0673e-02

9.3193e-06

-0.4070

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr2:95145291-95146745:-

ESCA

EER

ENSG00000117650.8

chr1

211663402:211663628:211667105:211667231

-0.4083

1.0620e-03

1.1953e-06

-0.4052

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

ENSG00000144029.10,MRPS5

ESCA

EAG

ENSG00000117650.8

chr1

211663402:211663628:211667105:211667231

-0.4083

1.1828e-03

1.4019e-06

-0.4028

ADAR;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SBDS;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

ENSG00000144029.10,MRPS5

ESCA

EAG

ENSG00000163625.11

chr4

84803289:84803467:84808333:84808417:84809886:84810107

-0.3178

1.5523e-02

1.2335e-05

-0.4019

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr2:95145291-95146745:-

GBM

EER

ENSG00000186166.4

chr11

119011948:119012003:119012148:119012177:119012114:119012177

0.3462

4.8834e-03

5.1983e-07

0.4038

Mast_cells_resting

GSVA_HALLMARK_FATTY_ACID_METABOLISM

ENSG00000144029.10,MRPS5

GBM

EAG

ENSG00000186166.4

chr11

119011948:119012003:119012148:119012177:119012114:119012177

0.3495

4.9036e-03

4.1633e-07

0.4069

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184

Mast_cells_resting

GSVA_HALLMARK_FATTY_ACID_METABOLISM

ENSG00000144029.10,MRPS5

KIRP

EAG

ENSG00000116977.14

chr1

236540246:236542787:236542914:236542990

-0.2720

2.1811e-04

6.4471e-09

-0.4036

ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG

LGALS8

B_cells_naive

GSVA_HALLMARK_MTORC1_SIGNALING

More results

Top

5. Enriched editing regions and immune infiltration for MRPS5

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000144029.10,MRPS5	ACC	EAG	B_cells_naive	3.1100e-02	0.3292
chr2:95145291-95146745:-	BLCA	EER	T_cells_CD4_memory_activated	5.8123e-04	0.1817
ENSG00000144029.10,MRPS5	BLCA	EAG	T_cells_CD4_memory_activated	4.3163e-04	0.1856
chr2:95145291-95146745:-	BRCA	EER	NK_cells_activated	3.0989e-03	0.0921
ENSG00000144029.10,MRPS5	BRCA	EAG	NK_cells_activated	2.3838e-03	0.0946
chr2:95145291-95146745:-	CESC	EER	Mast_cells_activated	1.9201e-03	0.1961
ENSG00000144029.10,MRPS5	CESC	EAG	Mast_cells_activated	2.0802e-03	0.1946
chr2:95145291-95146745:-	COAD	EER	T_cells_regulatory_(Tregs)	4.3410e-02	0.1395
ENSG00000144029.10,MRPS5	COAD	EAG	T_cells_regulatory_(Tregs)	4.3410e-02	0.1395
chr2:95145291-95146745:-	DLBC	EER	Mast_cells_activated	9.1193e-03	0.5671
ENSG00000144029.10,MRPS5	DLBC	EAG	Mast_cells_activated	9.4547e-03	0.5521
chr2:95145291-95146745:-	ESCA	EER	T_cells_regulatory_(Tregs)	6.8666e-03	-0.2221
ENSG00000144029.10,MRPS5	ESCA	EAG	T_cells_regulatory_(Tregs)	6.7894e-03	-0.2224
chr2:95145291-95146745:-	GBM	EER	T_cells_follicular_helper	2.1590e-02	-0.1914
ENSG00000144029.10,MRPS5	GBM	EAG	T_cells_follicular_helper	2.2831e-02	-0.1896
chr2:95145291-95146745:-	HNSC	EER	Monocytes	4.6331e-02	0.1386
ENSG00000144029.10,MRPS5	HNSC	EAG	Monocytes	3.7086e-02	0.1440
chr2:95145291-95146745:-	KIRC	EER	B_cells_naive	1.9555e-02	0.1248
ENSG00000144029.10,MRPS5	KIRC	EAG	B_cells_naive	2.1451e-02	0.1229
chr2:95145291-95146745:-	KIRP	EER	T_cells_CD4_memory_resting	5.0061e-06	-0.2910
ENSG00000144029.10,MRPS5	KIRP	EAG	T_cells_CD4_memory_resting	6.0563e-06	-0.2885
chr2:95145291-95146745:-	LUAD	EER	T_cells_CD4_memory_activated	1.9690e-04	0.1882
ENSG00000144029.10,MRPS5	LUAD	EAG	T_cells_CD4_memory_activated	3.1782e-04	0.1818
chr2:95145291-95146745:-	LUSC	EER	Mast_cells_activated	1.7815e-03	0.1604
ENSG00000144029.10,MRPS5	LUSC	EAG	Mast_cells_activated	2.5009e-03	0.1551
chr2:95145291-95146745:-	MESO	EER	Macrophages_M1	4.7527e-02	-0.2344
ENSG00000144029.10,MRPS5	MESO	EAG	Macrophages_M1	4.7527e-02	-0.2344
chr2:95145291-95146745:-	OV	EER	Eosinophils	3.0764e-03	0.2033
ENSG00000144029.10,MRPS5	OV	EAG	Eosinophils	2.3230e-03	0.2071
chr2:95145291-95146745:-	PAAD	EER	Eosinophils	8.2999e-05	0.3108
ENSG00000144029.10,MRPS5	PAAD	EAG	Eosinophils	8.3231e-05	0.3107
chr2:95145291-95146745:-	PCPG	EER	T_cells_gamma_delta	8.2951e-05	0.3079
ENSG00000144029.10,MRPS5	PCPG	EAG	T_cells_gamma_delta	8.2951e-05	0.3079
chr2:95145291-95146745:-	SARC	EER	Macrophages_M2	1.1826e-02	0.1698
ENSG00000144029.10,MRPS5	SARC	EAG	Macrophages_M2	1.3195e-02	0.1669
chr2:95145291-95146745:-	SKCM	EER	T_cells_regulatory_(Tregs)	4.5551e-05	0.2129
ENSG00000144029.10,MRPS5	SKCM	EAG	T_cells_regulatory_(Tregs)	6.6287e-05	0.2081
chr2:95145291-95146745:-	STAD	EER	Dendritic_cells_activated	4.1084e-02	0.1270
ENSG00000144029.10,MRPS5	STAD	EAG	Dendritic_cells_activated	3.4074e-02	0.1312
chr2:95145291-95146745:-	TGCT	EER	T_cells_regulatory_(Tregs)	3.2200e-03	-0.2414
ENSG00000144029.10,MRPS5	TGCT	EAG	T_cells_regulatory_(Tregs)	3.2200e-03	-0.2414
chr2:95145291-95146745:-	THCA	EER	T_cells_regulatory_(Tregs)	4.2889e-03	0.1315
ENSG00000144029.10,MRPS5	THCA	EAG	Dendritic_cells_activated	6.6003e-03	0.1250
chr2:95145291-95146745:-	THYM	EER	T_cells_regulatory_(Tregs)	1.1438e-02	0.2425
ENSG00000144029.10,MRPS5	THYM	EAG	T_cells_regulatory_(Tregs)	1.1438e-02	0.2425
chr2:95145291-95146745:-	UCEC	EER	T_cells_CD4_naive	8.7147e-05	0.3255
ENSG00000144029.10,MRPS5	UCEC	EAG	T_cells_CD4_naive	6.7109e-05	0.3304
chr2:95145291-95146745:-	UCS	EER	B_cells_naive	1.9182e-02	-0.3238
ENSG00000144029.10,MRPS5	UCS	EAG	B_cells_naive	1.8056e-02	-0.3268

Top

6. Enriched editing regions and immune gene sets for MRPS5

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr2:95145291-95146745:-	BRCA	EER	6.4066e-03		2.7055e-03	0.0934
ENSG00000144029.10,MRPS5	BRCA	EAG	7.0601e-03		4.5331e-03	0.0884

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr2:95145291-95146745:-	LUAD	EER	6.3923e-03	0.1384	9.5734e-03	0.1316	3.8541e-03	0.1466	3.1786e-02	0.1092
ENSG00000144029.10,MRPS5	LUAD	EAG	1.1483e-02	0.1282	1.8490e-02	0.1196	7.2090e-03	0.1362	4.1345e-02	0.1036

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr2:95145291-95146745:-	BLCA	GSVA_HALLMARK_COMPLEMENT	EER	3.3741e-05	0.2182
ENSG00000144029.10,MRPS5	BLCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	6.4489e-05	0.2101
ENSG00000144029.10,MRPS5	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	6.0575e-19	0.2721
chr2:95145291-95146745:-	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.5292e-20	0.2814
ENSG00000144029.10,MRPS5	CESC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	7.9594e-03	0.1682
chr2:95145291-95146745:-	CESC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	7.2483e-03	0.1701
chr2:95145291-95146745:-	CHOL	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	3.9488e-03	0.4748
ENSG00000144029.10,MRPS5	CHOL	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	3.9488e-03	0.4748
chr2:95145291-95146745:-	COAD	GSVA_HALLMARK_COMPLEMENT	EER	5.6176e-03	0.1905
ENSG00000144029.10,MRPS5	COAD	GSVA_HALLMARK_COMPLEMENT	EAG	5.6176e-03	0.1905
ENSG00000144029.10,MRPS5	DLBC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	3.4177e-02	-0.4638
chr2:95145291-95146745:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	6.3616e-03	0.2241
ENSG00000144029.10,MRPS5	ESCA	GSVA_HALLMARK_P53_PATHWAY	EAG	5.8058e-03	0.2265
chr2:95145291-95146745:-	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	1.8642e-03	0.2571
ENSG00000144029.10,MRPS5	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	2.0305e-03	0.2551
chr2:95145291-95146745:-	HNSC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	2.1498e-02	0.1597
ENSG00000144029.10,MRPS5	HNSC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.3193e-02	0.1708
ENSG00000144029.10,MRPS5	KIRC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	3.9333e-12	0.3597
chr2:95145291-95146745:-	KIRC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	3.3529e-12	0.3608
chr2:95145291-95146745:-	KIRP	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.1147e-07	0.3287
ENSG00000144029.10,MRPS5	KIRP	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.7777e-07	0.3306
chr2:95145291-95146745:-	LGG	GSVA_HALLMARK_ADIPOGENESIS	EER	1.1345e-08	0.2492
ENSG00000144029.10,MRPS5	LGG	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.1297e-08	0.2492
ENSG00000144029.10,MRPS5	LIHC	GSVA_HALLMARK_COAGULATION	EAG	1.0291e-03	0.2913
chr2:95145291-95146745:-	LIHC	GSVA_HALLMARK_COAGULATION	EER	1.0291e-03	0.2913
ENSG00000144029.10,MRPS5	LUAD	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	3.0576e-05	0.2100
chr2:95145291-95146745:-	LUAD	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.3002e-05	0.2196
chr2:95145291-95146745:-	LUSC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	2.0333e-04	0.1902
ENSG00000144029.10,MRPS5	LUSC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	1.9500e-04	0.1905
ENSG00000144029.10,MRPS5	MESO	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	7.5229e-04	0.3882
chr2:95145291-95146745:-	MESO	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	7.5229e-04	0.3882
ENSG00000144029.10,MRPS5	OV	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	8.4920e-03	0.1795
chr2:95145291-95146745:-	OV	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.4313e-03	0.2011
chr2:95145291-95146745:-	PAAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	7.8808e-03	0.2127
ENSG00000144029.10,MRPS5	PAAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	8.0280e-03	0.2122
ENSG00000144029.10,MRPS5	PCPG	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.7344e-02	0.1891
chr2:95145291-95146745:-	PCPG	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.7344e-02	0.1891
chr2:95145291-95146745:-	PRAD	GSVA_HALLMARK_ADIPOGENESIS	EER	1.2838e-02	0.1216
ENSG00000144029.10,MRPS5	PRAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.8007e-02	0.1154
ENSG00000144029.10,MRPS5	READ	GSVA_HALLMARK_P53_PATHWAY	EAG	7.5006e-05	0.4183
chr2:95145291-95146745:-	READ	GSVA_HALLMARK_P53_PATHWAY	EER	7.3332e-05	0.4188
chr2:95145291-95146745:-	SARC	GSVA_HALLMARK_COMPLEMENT	EER	3.3352e-10	0.4082
ENSG00000144029.10,MRPS5	SARC	GSVA_HALLMARK_COMPLEMENT	EAG	6.5401e-09	0.3787
chr2:95145291-95146745:-	SKCM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	6.1460e-06	0.2354
ENSG00000144029.10,MRPS5	SKCM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.6378e-05	0.2190
ENSG00000144029.10,MRPS5	STAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	5.8734e-03	-0.1701
chr2:95145291-95146745:-	STAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	5.0492e-03	0.1737
chr2:95145291-95146745:-	TGCT	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.3437e-08	0.4473
ENSG00000144029.10,MRPS5	TGCT	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.3437e-08	0.4473
ENSG00000144029.10,MRPS5	THCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.3842e-07	0.2398
chr2:95145291-95146745:-	THCA	GSVA_HALLMARK_GLYCOLYSIS	EER	6.2511e-07	0.2274
chr2:95145291-95146745:-	THYM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.2485e-02	-0.2397
ENSG00000144029.10,MRPS5	THYM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.2485e-02	-0.2397
ENSG00000144029.10,MRPS5	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.1707e-03	-0.2716
chr2:95145291-95146745:-	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.0645e-03	-0.2738
chr2:95145291-95146745:-	UCS	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	6.2325e-05	0.5259
ENSG00000144029.10,MRPS5	UCS	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	5.9951e-05	0.5269
chr2:95145291-95146745:-	UVM	GSVA_HALLMARK_UV_RESPONSE_UP	EER	9.6884e-05	0.4747
ENSG00000144029.10,MRPS5	UVM	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	9.6884e-05	0.4747

Top

7. Enriched editing regions and drugs for MRPS5

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr2:95145291-95146745:-	ACC	Erlotinib	EER	6.7147e-05	-0.5696
ENSG00000144029.10,MRPS5	ACC	AUY922	EAG	8.3032e-03	-0.3975
chr2:95145291-95146745:-	BLCA	CMK	EER	1.4751e-04	-0.2001
ENSG00000144029.10,MRPS5	BLCA	CI.1040	EAG	2.0570e-04	-0.1955
ENSG00000144029.10,MRPS5	BRCA	A.770041	EAG	4.2650e-09	-0.1819
chr2:95145291-95146745:-	BRCA	A.770041	EER	3.7225e-09	-0.1827
ENSG00000144029.10,MRPS5	CESC	ABT.263	EAG	2.1950e-03	0.1936
chr2:95145291-95146745:-	CESC	ABT.263	EER	2.2009e-03	0.1936
chr2:95145291-95146745:-	COAD	AZD8055	EER	5.5382e-03	-0.1908
ENSG00000144029.10,MRPS5	COAD	AZD8055	EAG	5.5382e-03	-0.1908
ENSG00000144029.10,MRPS5	DLBC	BIRB.0796	EAG	7.0902e-03	-0.5691
chr2:95145291-95146745:-	DLBC	BIRB.0796	EER	2.5938e-02	-0.4966
ENSG00000144029.10,MRPS5	ESCA	CCT018159	EAG	7.0034e-07	-0.3958
chr2:95145291-95146745:-	ESCA	CCT018159	EER	4.5432e-07	-0.4018
chr2:95145291-95146745:-	GBM	AMG.706	EER	7.3226e-03	0.2226
ENSG00000144029.10,MRPS5	GBM	FTI.277	EAG	8.3067e-03	0.2192
ENSG00000144029.10,MRPS5	HNSC	GSK269962A	EAG	1.1287e-02	0.1745
chr2:95145291-95146745:-	HNSC	BIRB.0796	EER	2.2638e-02	0.1584
ENSG00000144029.10,MRPS5	KICH	EHT.1864	EAG	4.3146e-02	-0.3029
ENSG00000144029.10,MRPS5	KIRC	BIRB.0796	EAG	2.2903e-04	0.1960
chr2:95145291-95146745:-	KIRC	BIRB.0796	EER	2.0046e-04	0.1978
chr2:95145291-95146745:-	KIRP	Bosutinib	EER	1.2308e-08	0.3587
ENSG00000144029.10,MRPS5	KIRP	Bosutinib	EAG	1.4140e-08	0.3573
chr2:95145291-95146745:-	LAML	EHT.1864	EER	1.7944e-02	-0.3240
ENSG00000144029.10,MRPS5	LAML	EHT.1864	EAG	1.7944e-02	-0.3240
ENSG00000144029.10,MRPS5	LGG	BAY.61.3606	EAG	8.4980e-07	0.2158
chr2:95145291-95146745:-	LGG	BAY.61.3606	EER	8.2041e-07	0.2161
ENSG00000144029.10,MRPS5	LIHC	CHIR.99021	EAG	7.3771e-03	0.2705
chr2:95145291-95146745:-	LIHC	CHIR.99021	EER	7.3771e-03	0.2705
ENSG00000144029.10,MRPS5	LUAD	Docetaxel	EAG	8.1243e-03	-0.1342
chr2:95145291-95146745:-	LUAD	Docetaxel	EER	6.4967e-03	-0.1381
ENSG00000144029.10,MRPS5	LUSC	BIRB.0796	EAG	6.6313e-03	0.1394
chr2:95145291-95146745:-	LUSC	BIRB.0796	EER	1.4127e-02	0.1263
ENSG00000144029.10,MRPS5	MESO	JNJ.26854165	EAG	1.2166e-03	-0.3739
chr2:95145291-95146745:-	MESO	JNJ.26854165	EER	1.2166e-03	-0.3739
ENSG00000144029.10,MRPS5	OV	JNK.9L	EAG	2.7452e-06	0.3142
chr2:95145291-95146745:-	OV	JNK.9L	EER	7.0483e-06	0.3044
chr2:95145291-95146745:-	PAAD	BIBW2992	EER	5.9169e-04	0.2729
ENSG00000144029.10,MRPS5	PAAD	BIBW2992	EAG	5.8003e-04	0.2733
ENSG00000144029.10,MRPS5	PCPG	Embelin	EAG	3.3978e-03	0.2317
chr2:95145291-95146745:-	PCPG	Embelin	EER	3.3978e-03	0.2317
chr2:95145291-95146745:-	PRAD	Methotrexate	EER	1.2415e-02	0.1226
ENSG00000144029.10,MRPS5	PRAD	Methotrexate	EAG	2.4032e-02	0.1105
ENSG00000144029.10,MRPS5	READ	CCT018159	EAG	4.9256e-04	-0.3720
chr2:95145291-95146745:-	READ	CCT018159	EER	9.8071e-04	-0.3532
chr2:95145291-95146745:-	SARC	Cisplatin	EER	4.1204e-09	-0.3841
ENSG00000144029.10,MRPS5	SARC	Cisplatin	EAG	1.0422e-08	-0.3739
chr2:95145291-95146745:-	SKCM	AG.014699	EER	3.7937e-08	0.2848
ENSG00000144029.10,MRPS5	SKCM	AG.014699	EAG	5.0966e-08	0.2819
ENSG00000144029.10,MRPS5	STAD	Embelin	EAG	3.5301e-03	0.1800
chr2:95145291-95146745:-	STAD	Embelin	EER	4.0956e-03	0.1778
ENSG00000144029.10,MRPS5	TGCT	Cyclopamine	EAG	7.4524e-06	-0.3601
chr2:95145291-95146745:-	TGCT	Cyclopamine	EER	7.4524e-06	-0.3601
ENSG00000144029.10,MRPS5	THCA	BIRB.0796	EAG	8.6696e-07	0.2244
chr2:95145291-95146745:-	THCA	CCT007093	EER	2.8403e-08	0.2526
ENSG00000144029.10,MRPS5	THYM	AS601245	EAG	2.5251e-03	0.2878
chr2:95145291-95146745:-	THYM	AS601245	EER	2.5251e-03	0.2878
ENSG00000144029.10,MRPS5	UCEC	GDC.0449	EAG	2.5637e-06	-0.3855
chr2:95145291-95146745:-	UCEC	GDC.0449	EER	4.6781e-06	-0.3760
chr2:95145291-95146745:-	UCS	AZ628	EER	1.3360e-03	-0.4332
ENSG00000144029.10,MRPS5	UCS	AZ628	EAG	1.3171e-03	-0.4337
ENSG00000144029.10,MRPS5	UVM	JNJ.26854165	EAG	1.9703e-03	-0.3855
chr2:95145291-95146745:-	UVM	JNJ.26854165	EER	1.9703e-03	-0.3855

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType